RayKnowChina Research Map
Shortlist0

RecruitingNeuromyelitis optica spectrum disorderPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Ofatumumab in AQP4-IgG Seropositive NMOSD

An open trial on neuromyelitis optica spectrum disorder, registered on ClinicalTrials.gov. Led by Tangdu Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTangdu Hospital空军军医大学唐都医院Xi'anHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05504694, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Expanded disability status scale (EDSS) score between 0 and 7.5 (inclusive).

    Inclusion criterion 4

  3. Positive for HBV or HCV.

    Exclusion criterion 7

    History of malignancy in past 5 years, including solid tumor, malignant hematopathy and carcinoma in situ.

    Exclusion criterion 10

  4. Effective contraception was used for female patients with fertility during the treatment or at least 3 months after stopping medication.

    Inclusion criterion 7

    Pregnant or breastfeeding patients and those with family planning during the study period.

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05504694, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Diagnosis of NMOSD according to the 2015 International Panel Diagnostic Criteria for NMOSD with AQP4-IgG.
  • Clinical evidence of at least 2 relapses (including first attack) in past 24 months with at least 1 relapse occurring in the preceding 12 months.
  • Adults aged ≥18 years old.
  • Expanded disability status scale (EDSS) score between 0 and 7.5 (inclusive).
  • Provision of written informed consent to participate in this study.
  • Only oral corticosteroids were permitted at screening (≤10mg equivalent per day), which should be terminated within one month.
  • Effective contraception was used for female patients with fertility during the treatment or at least 3 months after stopping medication.

Exclusion Criteria:

  • Progressive neurological deterioration unrelated to relapses of NMOSD, or presence of neurological findings suspected with PML.
  • Pregnant or breastfeeding patients and those with family planning during the study period.
  • Patients participating in any other clinical therapeutic study at the screening or within 30 days of screening.
  • Patients with splenectomy or history of no spleen, and those with planned surgery (excluding minor surgery) during the study period.
  • Presence of uncontrolled severe concurrent diseases; long-term glucocorticoids or immunosuppressants use due to other autoimmune diseases, or presence of other chronic diseases that cannot receiving immunosuppression.
  • Active infection at within 4 weeks before baseline.
  • Positive for HBV or HCV.
  • Evidence of latent or active tuberculosis (TB).
  • Have received any live or live-attenuated vaccine within 6 weeks before baseline.
  • History of malignancy in past 5 years, including solid tumor, malignant hematopathy and carcinoma in situ.
  • History of severe allergic reactions to biological agents.
  • Inability to provide written informed consent.

Quoted from ClinicalTrials.gov, NCT05504694, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05504694, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05504694